It activates receptors for both GLP-1 and GIP, leading to a powerful double whammy: Enhanced Insulin & Reduced Glucagon Tirzepatide significantly increases insulin production and lowers glucagon secretion, a hormone that raises blood sugar
What the preclinical data offer is a biologically grounded rationale for the direction of travel, and a framework for designing the human studies that will ultimately determine how much of this neuroprotective potential translates into clinical benefit
When administered as a medication, it mimics these effects, making patients feel fuller longer, eat smaller portions, and experience fewer cravings
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: A multicenter real-world study
If your insurer has denied Foundayo or another GLP-1 drug, do not give up